RxDoctor Payments Data

Travis Wiggins, MD

Gastroenterology · Savannah, GANPI 1053486126

Payments from drug & device makers

$3,347in general payments, 2019–2025

Across 131 payments — averaging $25.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$950
  • Fujifilm Healthcare Americas Corporation$659
  • Takeda Pharmaceuticals U.S.A., Inc.$215
  • Boston Scientific$210
  • Madrigal Pharmaceuticals$181
  • Pfizer$156
  • plus $976 from 25 others

What the payments were for

  • Food & beverage$2,60478%
  • Education$853%
  • Gifts$65920%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,347 in reported general payments places this provider in the 40th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$224,108
Medicare patients
598
Services billed
5,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab38$387,409
StelaraUstekinumab13$340,300
LinzessLinaclotide87$73,212
CreonLipase/Protease/Amylase15$41,993
VemlidyTenofovir Alafenamide12$17,689
TrulancePlecanatide30$17,181
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates204$13,455
LialdaMesalamine14$6,677
Dexlansoprazole DrDexlansoprazole18$5,244
Colesevelam Hcl43$5,213
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl312$4,719
Omeprazole290$3,159
Pantoprazole Sodium135$1,825
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl108$1,780
Lubiprostone14$1,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$85$340,30013 claims
AbbVieLinzess, Creon$950$115,205102 claims
GileadVemlidy$41$17,68912 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$124$17,18130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →